Evaluation of risk stratification using gene expression assays in patients with breast cancer receiving neoadjuvant chemotherapy
ConclusionsTo our knowledge, this is the largest study using a nationwide oncology database suggesting that high recurrence risk groups in both assays were associated with pCR. Among those with favorable hormone receptor status, RS ≥ 31 may be a more selective prognostic marker for pCR.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Databases & Libraries | Genetics | Hormones | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Study | Women